recent
advanc
molecular
genet
pathogenesi
immunolog
provid
optim
framework
develop
novel
approach
ration
design
vaccin
effect
viral
epizoot
diseas
paper
review
viralvector
base
antigen
deliveri
system
adss
recent
develop
vaccin
test
veterinari
speci
includ
attenu
viru
dna
rna
viral
vector
besid
use
vaccinolog
adss
constitut
invalu
tool
research
understand
natur
protect
respons
differ
speci
open
possibl
modul
potenti
relev
immun
mechan
involv
protect
vaccin
besid
earli
detect
warn
system
remain
costeffect
mean
prevent
spread
viral
infecti
diseas
mani
year
consider
scientif
effort
direct
toward
develop
novel
vaccin
technolog
mainli
aim
improv
perform
safeti
classic
vaccin
either
inactiv
base
modifi
live
viru
mani
deliveri
system
provid
power
platform
check
immunogen
trigger
specif
immun
respons
target
antigen
well
unveil
immun
mechan
involv
protect
diseas
current
knowledg
viral
dna
rna
vector
carrier
foreign
antigen
illustr
mani
potenti
approach
antigen
deliveri
develop
veterinari
vaccin
consider
develop
veterinari
vaccin
differ
human
respect
one
import
cost
sinc
depend
speci
vaccin
high
cost
may
preclud
use
certain
type
vaccin
requir
vaccin
boost
cours
contribut
greatli
cost
increas
import
design
veterinari
vaccin
abil
distinguish
infect
vaccin
anim
diva
particularli
import
erad
campaign
sinc
enabl
countri
gain
diseas
free
statu
readili
consider
particularli
diseas
outbreak
time
taken
induc
protect
potenti
environment
spread
vaccin
includ
nontarget
speci
particular
challeng
develop
veterinari
vaccin
limit
fundament
knowledg
reagent
studi
protect
immun
respons
veterinari
speci
interestingli
first
vaccin
ever
use
becam
one
wide
use
system
vaccin
antigen
deliveri
poxviru
vector
sinc
mani
dna
virus
includ
adenovirus
herpesvirus
baculovirus
proven
use
develop
vaccin
approach
recent
refin
revers
genet
technolog
allow
rescu
attenu
rna
virus
use
potenti
express
deliveri
vector
paper
review
deliveri
system
base
viral
vector
commonli
use
basic
appli
veterinari
vaccin
research
live
attenu
vaccin
first
form
vaccin
success
use
mani
year
target
number
econom
import
anim
diseas
also
companion
anim
diseas
advanc
molecular
biolog
recent
year
allow
problem
concern
encount
develop
use
live
attenu
vaccin
address
live
attenu
viru
vaccin
live
viru
lost
virul
maintain
abil
induc
protect
immun
virul
viru
mani
advantag
inactivatedkil
viru
compon
vaccin
includ
fact
viru
protein
express
present
broad
spectrum
epitop
immun
system
moreov
sinc
viru
protein
express
insid
cell
present
associ
mhc
class
molecul
stimul
cytotox
cell
respons
addit
administr
natur
rout
infect
via
nasal
mucosa
eg
influenza
mimic
infect
local
site
abl
induc
effect
long
last
appropri
humor
cellmedi
immun
respons
well
induc
innat
immun
respons
advantag
live
attenu
viru
vaccin
includ
low
reactiv
induct
system
respons
lead
enhanc
protect
diseas
induct
mucos
respons
importantli
pharmaceut
compani
rel
low
manufactur
cost
requir
minim
downstream
process
requir
adjuv
formul
howev
given
advantag
live
attenu
vaccin
consid
ideal
vaccin
due
overal
safeti
profil
potenti
genet
unstabl
may
caus
problem
immunocompromis
host
pregnanc
eg
rubella
recent
exampl
use
monoval
vaccin
itali
caus
undesir
effect
attribut
inadequ
attenu
european
sheep
live
attenu
viru
vaccin
prepar
either
natur
occur
viru
anoth
speci
eg
jenner
cowpox
artifici
attenu
tradit
methodolog
produc
live
attenu
vaccin
often
involv
blind
serial
passag
virul
isol
heterolog
tissu
cell
cultur
egg
laboratori
anim
attenu
mutant
produc
method
produc
attenu
viru
gener
mutant
either
chemic
treatment
heat
spontan
mutagenesi
subsequ
clonal
select
problem
mutat
attenu
way
uncontrol
random
process
often
induc
mutat
map
genom
level
therefor
difficult
control
level
attenu
maintain
antigen
although
live
attenu
vaccin
success
form
vaccin
revers
virul
differ
virul
differ
host
alway
singl
greatest
risk
associ
use
first
success
use
attenu
vaccin
edward
jenner
inocul
boy
cowpox
subsequ
protect
boy
challeng
smallpox
first
artifici
creat
attenu
vaccin
rabi
produc
loui
pasteur
recent
report
summaris
benefit
human
dog
mass
rabi
vaccin
program
domest
dog
differ
part
world
one
success
appli
attenu
vaccin
plowright
vaccin
strain
use
combat
rinderpest
highli
pathogen
often
fatal
mortal
diseas
cattl
buffalo
vaccin
strain
deriv
serial
passag
cell
cultur
highli
pathogen
kabet
strain
rinderpest
viru
plowright
vaccin
instrument
near
erad
rinderpest
particular
attenu
vaccin
meet
mani
requir
good
vaccin
stimul
strong
immun
respons
confer
lifelong
immun
singl
inocul
also
highli
unlik
revert
virul
form
attenu
gener
sever
small
chang
locat
throughout
genom
less
success
attenu
vaccin
use
rift
valley
fever
african
hors
sick
african
swine
fever
name
rift
valley
fever
insect
born
multispeci
zoonot
viral
diseas
livestock
caus
rift
valley
fever
viru
attenu
vaccin
base
smithburn
isol
deriv
mosquito
passag
time
intracerebr
inocul
mice
result
loss
hepatotrop
acquisit
neurotrop
vaccin
administ
parenter
immunis
sheep
million
dose
wide
use
africa
howev
vaccin
base
smithburn
isol
induc
abort
teratolog
foetus
vaccin
anim
hydrop
amnii
prolong
gestat
proport
vaccin
dam
research
ongo
find
safer
attenu
vaccin
one
possibl
replac
name
clone
shown
trial
highli
efficaci
sheep
cattl
induc
abort
sheep
problem
due
insuffici
attenu
vaccin
strain
also
encount
african
hors
sick
ah
vector
born
viral
diseas
equida
result
high
mortal
suscept
hors
african
swine
fever
viru
acut
fatal
haemorrhag
fever
domest
pig
failur
develop
effect
live
attenu
vaccin
mention
exampl
mainli
due
convent
methodolog
employ
addit
increas
stringenc
regulatori
bodi
driven
vaccin
develop
incorpor
latest
advanc
molecular
biolog
cell
biolog
immunolog
use
revers
genet
recombin
technolog
allow
vaccin
care
design
possibl
fulli
defin
attenu
mutat
clearli
map
viru
genom
logic
design
vaccin
strain
help
ensur
risk
aris
revers
virul
greatli
minimis
logic
design
vaccin
also
allow
immunomodulatori
gene
remov
attenu
viru
ensur
protect
antigen
accident
remov
henc
increas
efficaci
stimul
immun
system
vaccin
anim
great
advantag
design
vaccin
abil
includ
use
conjunct
epidemiolog
surveil
system
mani
case
diseas
endem
vaccin
consid
control
option
due
inabl
differenti
infect
anim
one
vaccin
develop
vaccin
allow
differenti
infect
vaccin
anim
diva
enabl
viru
free
statu
rapidli
grant
countri
suffer
diseas
incurs
introduct
excit
new
vaccin
technolog
peptidesrecombin
antigen
dna
viral
vector
attenu
live
vaccin
fashion
awhil
howev
develop
new
molecular
biolog
techniqu
see
return
attenu
vaccin
forefront
diseas
control
exampl
revers
genet
use
develop
latest
vaccin
avian
influenza
viru
potenti
use
avian
host
human
use
technolog
allow
identif
virul
determin
three
envelop
glycoprotein
classic
swine
fever
viru
csfv
sever
live
attenu
csfv
mutant
gener
confer
complet
protect
swine
challeng
rescu
virul
viru
earli
day
postvaccin
similar
success
experienc
use
molecular
tool
design
vaccin
diseas
caus
dna
virus
pseudorabi
aujeszki
diseas
combat
success
use
recombin
gene
delet
attenu
vaccin
first
commerci
avail
gene
delet
live
vaccin
glycoprotein
e
ge
delet
vaccin
use
erad
programm
europ
america
recent
new
gener
geggtkgen
delet
vaccin
develop
viralbas
vector
antigen
deliveri
system
poxvirus
provid
number
advantag
antigen
deliveri
system
larg
virus
contain
dna
genom
rang
size
kb
pair
accommod
larg
amount
kb
extra
dna
thu
sever
transgen
express
simultan
provid
multival
vaccin
approach
importantli
poxvirus
replic
within
cytoplasm
infect
cell
integr
host
genom
thu
elimin
potenti
insert
mutagenesi
poxvirus
use
two
differ
approach
vaccin
first
approach
reli
product
replic
attenu
strain
permiss
host
second
approach
reli
fact
poxvirus
may
enter
cell
nonpermiss
host
express
protein
encod
includ
insert
transgen
produc
infecti
viru
replicationdefici
virus
provid
advantag
term
safeti
although
disadvantag
one
inocul
may
requir
induc
protect
immun
respons
approach
use
vaccinia
viru
vv
wide
host
tropism
differ
poxvirus
restrict
host
tropism
replic
poxviru
vector
induc
longlast
immun
singl
inject
activ
humor
cellular
immun
depend
upon
promot
control
express
immunogen
possibl
use
poxvirus
vector
foreign
gene
express
initi
demonstr
vv
first
recombin
vv
use
field
copenhagen
strain
express
rabi
viru
surfac
glycoprotein
commerci
version
strain
embed
bait
rabor
vrg
use
erad
fox
rabi
sever
western
europ
countri
sinc
numer
strain
vv
engin
express
varieti
antigen
number
pathogen
variou
anim
speci
tabl
wild
type
vv
strain
may
produc
undesir
effect
human
therefor
two
highli
attenu
vaccinia
viru
vector
develop
modifi
vaccinia
ankara
mva
nyvac
strain
undergo
limit
product
replic
mammalian
cell
although
viru
protein
produc
includ
insert
transgen
therefor
humor
cellular
immun
induc
transgen
product
mva
strain
lost
genom
includ
host
rang
virul
gene
passag
chick
embryo
fibroblast
nyvac
strain
develop
recent
copenhagen
vv
vaccin
strain
target
delet
gene
strain
use
success
induc
protect
anim
pathogen
tabl
anim
poxvirus
attenu
use
replic
recombin
vaccin
permiss
host
speci
among
capripoxvirus
select
restrict
host
rang
attenu
strain
use
vector
express
h
f
gene
rinderpest
viru
recombin
virus
confer
protect
cattl
rinderpest
lumpi
skin
diseas
vaccin
express
either
h
f
gene
pest
de
petit
rumin
ppr
protect
goat
goatpox
ppr
vaccin
strain
also
use
express
sever
antigen
bluetongu
viru
sheep
provid
partial
full
protect
challeng
virul
strain
anoth
attenu
capripoxviru
lsdv
neethl
vaccin
strain
use
vector
deliv
antigen
lsdv
recombin
express
rabi
viru
glycoprotein
elicit
humor
cellmedi
immun
respons
cattl
interestingli
recombin
lsdv
strain
replic
mice
rabbit
still
induc
protect
immun
respons
rabi
anoth
lsdv
recombin
express
glycoprotein
rift
valley
fever
viru
also
induc
protect
rift
valley
fever
mice
numer
recombin
avipoxvirus
develop
control
avian
diseas
exampl
fowlpox
recombin
also
list
tabl
pigeonpox
viru
express
f
gene
newcastl
diseas
viru
also
safe
effici
chicken
rabbit
inject
attenu
myxoma
viru
express
influenza
viru
haemagglutinin
develop
specif
antibodi
respons
foreign
antigen
thu
suggest
myxoma
viru
could
effici
antigen
deliveri
system
rabbit
shortli
recombin
myxoma
virus
produc
protect
myxomatosi
rabbit
viral
haemorrhag
diseas
pig
recombin
swinepox
viru
develop
protect
virul
challeng
aujezski
diseas
viru
exampl
illustr
use
replic
poxvirus
permiss
host
speci
vaccin
strategi
howev
promis
knowledg
one
recombin
attenu
fowlpox
viru
express
gene
avian
influenza
viru
trovac
tm
use
commerci
limit
use
reflect
fact
recombin
genet
modifi
organ
replic
natur
host
speci
thu
caus
biosafeti
concern
addit
interf
preimmun
result
previou
natur
infect
transfer
matern
antibodi
young
may
reduc
capac
vector
replic
thu
induc
less
effect
immun
poxvirus
known
gener
nearli
lifelong
immun
natur
host
speci
initi
contact
advantag
poxviru
vector
use
naiv
anim
certainli
major
constraint
repeat
use
immun
anim
howev
recent
work
open
new
possibl
circumv
problem
preexist
immun
protein
primari
target
antibodi
neutral
extracellular
form
vv
mice
prime
replic
vv
boost
recombin
vv
lack
ectodomain
protein
stronger
antibodi
respons
transgen
product
compar
mice
boost
wild
type
recombin
vv
similar
strategi
could
envisag
poxvirus
use
vector
permiss
host
speci
altern
strategi
use
replicationdefici
poxviru
vector
nonpermiss
host
speci
inde
shown
mice
preexist
immun
nonrepl
mva
strong
enough
block
boost
vaccin
viru
poxviru
vector
studi
far
antigen
deliveri
nonpermiss
host
speci
avipoxvirus
use
mammal
avipoxvirus
replic
avian
cell
bird
mammalian
cell
mammal
initi
abort
infect
express
antigen
stimul
humor
cellmedi
immun
respons
transgen
product
recombin
fowlpox
virus
success
use
express
antigen
guinea
pig
cat
pig
recombin
canarypox
vector
time
effici
compar
fowlpox
vector
induc
protect
immun
studi
avipoxviru
antigen
deliveri
mammal
alvac
canarypox
strain
strain
use
induc
protect
divers
pathogen
variou
speci
despit
extens
use
research
commerci
applic
present
avail
companion
anim
hors
alvac
strain
develop
protect
dog
ferret
rabi
canin
distemp
viru
licens
canarypox
base
vaccin
also
list
tabl
nonrepl
recombin
poxvirus
offer
sever
advantag
includ
ad
safeti
sinc
spread
anim
also
induc
low
immun
vector
viru
use
thu
permit
repeat
administr
use
prime
young
anim
matern
antibodi
convent
attenu
live
vaccin
fail
also
boost
immun
respons
engend
kill
viru
vaccin
howev
compar
replic
poxvirus
use
permiss
host
speci
gener
requir
administr
high
titr
boost
inject
achiev
suffici
protect
exampl
immunis
sheep
bluetongu
viru
canarypox
viru
vaccin
requir
two
inject
particl
week
apart
one
dose
particl
recombin
capripox
viru
enough
protect
goat
pest
de
petit
rumin
final
replic
replicationdefici
recombin
poxviru
vaccin
offer
possibl
differenti
natur
infect
vaccin
anim
sinc
recombin
express
singl
coupl
antigen
pathogen
antigen
remain
avail
immunolog
test
viru
type
speci
orf
viru
orfv
genu
parapoxvirida
ppv
propos
candid
novel
marker
vector
vaccin
orfv
restrict
host
rang
vivo
vitro
sheep
goat
occasion
man
restrict
skin
tropism
absenc
system
infect
among
differ
orfv
vaccin
strain
highli
attenu
strain
markedli
reduc
pathogen
subcutan
applic
strain
present
sever
advantag
use
viral
vector
includ
abil
propag
cell
line
abil
induc
strong
immunestimul
regul
respons
nonpermiss
host
mice
swine
addit
benefit
vector
shortterm
vector
specif
immun
without
format
neutral
antibodi
ppv
induc
even
natur
host
sheep
thu
avoid
immun
interfer
follow
repeat
inocul
mainli
link
action
viru
immunomodulatori
protein
interf
host
immun
respons
avoid
viru
elimin
addit
observ
adjuv
properti
orfv
promot
orfv
new
safe
poxviru
vector
sever
vivo
studi
report
prophylact
administr
inactiv
baypamun
bayer
ag
leverkusen
germani
reduc
suscept
differ
anim
speci
infecti
diseas
ibr
viru
cattl
aujezski
diseas
swine
recent
immunostimulatori
properti
shown
follow
immunis
csfv
glycoprotein
subunit
vaccin
swine
studi
genom
highli
attenu
orfv
strain
led
identif
viral
gene
nonessenti
viru
replic
influenc
viral
pathogenesi
virul
host
immun
thu
delet
vegf
mammalian
vascular
endotheli
growth
factor
homologu
locu
permit
foreign
gene
express
vitro
even
absenc
product
viru
replic
nonpermiss
cell
lead
induct
specif
immun
respons
nonpermiss
host
sever
report
protect
capac
follow
inocul
differ
recombin
orfv
strain
summaris
tabl
conclus
although
studi
need
understand
immunostimulatori
properti
orfv
capabl
orfv
recombin
induc
antigen
specif
memori
immun
respons
control
acut
persist
infect
requir
differ
immun
mechan
demonstr
potenti
promis
new
poxviru
deliveri
system
famili
herpesvirida
encompass
subfamili
alpha
beta
gammaherpesvirina
contain
sever
genera
larg
genom
size
extend
presenc
virul
gene
essenti
product
viral
replic
vitro
vivo
avail
effici
method
manipul
herpesvir
genom
signific
advantag
use
herpesvirus
vaccin
vector
sever
herpesvirus
caus
diseas
pet
anim
husbandri
result
high
econom
loss
engin
serv
vaccin
vector
tabl
except
alphaherpesvirus
reflect
member
subfamili
caus
major
herpesvir
infect
signific
veterinari
relev
first
herpesvirus
farm
anim
engin
express
heterolog
antigen
bovin
herpesviru
type
caus
infecti
bovin
rhinotracheitisinfecti
pustular
balanoposth
pseudorabi
viru
prv
caus
aujeszki
diseas
virion
surfac
display
approach
use
fusion
protein
footandmouth
diseas
viru
fmdv
epitop
link
nterminu
glycoprotein
c
calv
immun
hybrid
recombin
protect
challeng
pathogen
develop
protect
antibodi
respons
fmdv
howev
followup
studi
use
similar
display
approach
publish
develop
vector
use
genom
higher
antibodi
titr
enhanc
frequenc
ifngamma
produc
pbmc
integr
express
cassett
code
structur
protein
bovin
respiratori
syncyti
viru
brsv
bovin
viral
diarrhoea
viru
bvdv
prv
cryptosporidium
parvum
parasit
caus
cryptosporidiosi
zoonot
diseas
integr
express
cassett
genom
result
replac
inactiv
pathogenicityassoci
gene
like
thymidin
kinas
gene
gene
encod
glycoprotein
gc
gg
ge
gi
analys
immunogen
properti
recombin
express
prv
glycoprotein
mice
reveal
induct
protect
immun
respons
lethal
challeng
prv
thu
recombin
might
benefici
situat
matern
antibodi
interfer
immun
piglet
prvbase
vaccin
recombin
herpesvirus
express
c
parvum
bvdv
inoccul
rabbit
guinea
pig
specif
antibodi
respons
appropri
pathogen
induc
knowledg
vaccinationchalleng
experi
cattl
report
brsv
attach
protein
g
express
vector
demonstr
vaccin
calv
resist
brsv
infect
howev
comparison
control
infect
virul
brsv
g
express
recombin
calv
increas
suitabl
canin
herpesviru
vector
immun
purpos
evalu
use
recombin
express
rabi
viru
g
protein
neospora
caninum
surfac
protein
vaccin
candid
elicit
specif
antibodi
respect
target
antigen
vaccinationchalleng
experi
howev
await
public
two
studi
report
vaccin
felin
leukemia
viru
flv
use
recombin
felin
herpesviru
effici
vaccin
achiev
immun
cat
recombin
express
env
protein
wherea
previou
vaccinationchalleng
experi
success
immun
recombin
express
env
gag
follow
booster
immun
baculoviru
express
env
gag
differ
vaccin
efficaci
might
due
intrins
characterist
recombin
recombin
insert
locu
tk
locu
respect
promot
use
direct
transcript
rou
sarcoma
ltr
promot
versu
human
cytomegaloviru
immedi
earli
promot
induct
protect
immun
respons
also
report
recombin
express
protein
toxoplasma
gondii
immun
cat
recombin
follow
challeng
infect
parasit
reduc
parasit
load
brain
serum
antibodi
inhibit
vitro
invas
tachyzoit
felin
caliciviru
neutral
antibodi
induc
cat
recombin
express
capsid
protein
felin
caliciviru
invitro
express
analys
report
far
vector
contain
gene
cassett
gag
env
protein
felin
immunodefici
viru
studi
suggest
result
recombin
might
suitabl
vaccin
candid
marek
diseas
viru
mdv
caus
highli
contagi
neoplast
diseas
chicken
engin
develop
polyval
vaccin
marek
diseas
md
newcastl
diseas
md
infecti
bursal
diseas
ibd
vaccin
challeng
experi
reveal
good
protect
diseas
target
respect
mdv
recombin
also
achiev
presenc
matern
antibodi
mdv
herpesviru
turkey
hvt
apathogen
chicken
use
long
time
vaccin
protect
md
bival
vaccin
md
ibd
base
hvt
vector
express
ibdv
shown
efficaci
safe
inocul
embryon
egg
chicken
effect
presenc
high
titr
matern
deriv
antibodi
remark
result
vaccin
vaxxitex
r
hvt
ibd
far
licens
commercialis
anim
herpesviru
vector
base
product
develop
vector
bival
vaccin
poultri
diseas
includ
express
haemagglutinin
gene
encod
highli
pathogen
avian
influenza
virus
delet
mutant
infecti
laryngotrach
viru
mention
prv
one
first
anim
herpesviru
suggest
suitabl
bival
vaccin
vector
proof
concept
achiev
show
attenu
prv
express
envelop
glycoprotein
classic
swine
fever
viru
constitut
efficaci
safe
nontransmiss
vaccin
aujeszki
diseas
classic
swine
fever
despit
promis
result
vaccin
never
commercialis
main
reason
may
use
prvbase
vector
vaccin
favour
produc
due
concurr
initi
erad
program
prv
consequ
develop
prvbase
vector
vaccin
recent
resum
public
origin
mainli
research
institut
china
report
prv
recombin
express
antigen
japanes
enceph
viru
jev
fmdv
porcin
reproduct
respiratori
syndrom
viru
prrsv
transmiss
gastroenter
viru
tgev
porcin
circoviru
fmdv
plu
porcin
parvoviru
ppv
rabi
viru
swine
influenza
viru
data
vaccinationchalleng
experi
potenti
vaccin
candid
avail
recombin
express
jev
fmdv
prrsv
haemagglutinin
swine
influenza
viru
induc
specif
immun
respons
prv
target
pathogen
howev
case
need
improv
interest
see
prv
vector
construct
find
way
field
applic
recombin
herpesvirus
describ
gener
use
classic
recombin
cultur
cell
mammalian
avian
origin
last
year
clone
maintain
entir
infecti
herpesvir
genom
escherichia
coli
socal
bacteri
artifici
chromosom
bac
develop
techniqu
manipul
genom
bacteria
significantli
eas
construct
recoveri
recombin
bac
techniqu
appli
gener
equin
herpesviru
recombin
express
bvdv
structur
protein
west
nile
viru
wnv
prm
e
protein
latter
induc
wnv
neutral
antibodi
immun
hors
vaccin
cattl
recombin
result
bvdvspecif
neutral
antibodi
reduct
viraemia
level
nasal
viru
shed
bvdv
challeng
infect
show
vector
suitabl
vaccin
cattl
may
find
applic
case
exist
antibodi
preclud
use
live
vector
vaccin
deriv
bovin
virus
like
recombin
virus
report
recent
express
bvdv
glycoprotein
gd
inocul
recombin
rabbit
sheep
induc
neutral
antibodi
respect
target
pathogen
howev
vaccinationchalleng
experi
cattl
need
elucid
whether
gammaherpesviru
regard
apathogen
low
pathogen
cattl
may
becom
suitabl
live
vector
vaccin
bovin
diseas
regard
commercialis
anim
herpesviru
vector
vaccin
far
success
stori
howev
develop
test
anim
model
target
anim
speci
significantli
contribut
understand
biolog
relev
veterinari
diseas
help
rational
design
futur
develop
improv
efficaci
might
includ
coexpress
immunostimulatori
protein
like
cytokin
chemokin
andor
ligand
activ
specif
signal
transduct
pathway
approach
facilit
bac
technolog
adenovirus
ad
isol
human
mani
anim
includ
bovin
ovin
porcin
canin
avian
speci
human
ad
far
best
characteris
vast
major
gene
transfer
studi
involv
ad
whether
therapeut
vaccin
purpos
carri
vector
deriv
serotyp
ad
adenovirusbas
vector
attract
candid
vaccin
develop
mammalian
host
elicit
potent
humor
cellmedi
immun
respons
ir
system
local
site
antigen
encod
insert
foreign
gene
differ
strategi
construct
employ
depend
upon
whether
aim
obtain
replic
vector
adr
capabl
multipli
natur
permiss
host
rather
nonrepl
vector
incap
multipli
host
adr
numer
vaccin
trial
conduct
use
adr
adr
vector
led
conclus
adr
quantit
diminut
requir
dose
qualit
induct
mucos
immun
effect
nevertheless
adr
vector
present
major
drawback
use
permiss
host
give
rise
product
infecti
particl
releas
environ
view
legisl
govern
use
genet
modifi
organ
use
adr
practic
conceiv
strain
ad
whose
innocu
firmli
establish
differ
vector
express
heterolog
antigen
compar
vector
proven
particularli
immunogen
notabl
regard
induct
antigenspecif
cell
qualiti
underpin
immunogen
yet
fulli
elucid
includ
capac
elicit
strong
innat
immun
parenter
administr
mice
induc
intens
inflammatori
respons
characteris
secret
high
level
proinflammatori
cytokin
induct
matur
process
immatur
dendrit
cell
cytokin
secret
initi
requir
viral
gene
express
rather
induc
viral
particl
inde
one
viral
structur
protein
hexon
describ
behav
intrins
adjuv
presenc
high
level
proinflammatori
cytokin
matur
dendrit
cell
presum
creat
condit
conduc
induct
antigenspecif
adapt
immun
regard
adapt
immun
memori
respons
elicit
observ
protract
murin
simian
studi
relat
typic
acut
viral
infect
particular
antigenspecif
tcell
popul
elicit
observ
maintain
effector
phenotyp
prolong
period
time
protract
memori
respons
may
relat
prolong
exposur
antigen
recent
studi
shown
high
level
antigen
express
maintain
week
parenter
administr
antigen
remain
avail
prime
cell
least
day
immunis
longterm
low
level
antigen
present
link
persist
low
level
transcript
activ
genom
site
inocul
liver
lymphat
tissu
vector
deriv
human
ad
extens
evalu
vaccin
murin
nonhuman
primat
model
less
data
gener
avail
veterinari
speci
although
remark
success
achiev
protect
swine
cattl
fmdv
mean
singl
inocul
subunit
vaccin
data
current
accumul
nonhuman
ad
murin
nonhuman
primat
speci
also
target
anim
speci
whether
repres
natur
host
necessari
preexist
immun
one
adenoviru
circumv
use
anoth
adenoviru
review
focus
nonhuman
ad
except
vaccin
oral
rout
data
obtain
human
ad
highli
instruct
vector
deriv
sever
anim
adenovirus
evalu
vaccin
deliv
parenter
rout
tabl
vector
deriv
porcin
ad
pav
use
vaccin
swine
csfv
pseudorabi
viru
one
studi
singl
dose
pav
express
csfv
induc
protect
virul
challeng
second
studi
administ
dna
prime
improv
protect
regard
two
dose
dna
singl
dose
likewis
administr
pav
vector
express
glycoprotein
pseudorabi
viru
protect
pig
diseas
virul
challeng
vector
deriv
ovin
ad
oav
evalu
murin
model
one
vector
express
nonstructur
protein
hepat
viru
shown
elicit
secret
cell
mice
vector
deriv
bovin
ad
bav
express
glycoprotein
gd
bovin
induc
protect
immun
respons
calv
regard
vector
deriv
canin
ad
serotyp
singl
administr
intramuscular
intranas
rout
vector
express
glycoprotein
rabi
viru
induc
protect
immun
mice
dog
subcutan
inocul
replicationcompet
elicit
antibodi
neutralis
infect
rabi
viru
protect
lethal
challeng
similarli
intramuscular
inocul
cat
elicit
rabiesvirusspecif
neutralis
antibodi
na
protect
administr
vector
express
protein
felin
panleukopenia
viru
elicit
neutralis
antibodi
na
cat
protect
infect
diseas
vector
express
protein
footandmouth
diseas
viru
gave
rise
humor
respons
includ
induct
na
pig
subcutan
vaccin
vector
express
canin
distemp
viru
cdv
antigen
afford
solid
protect
immun
puppi
born
cdv
immun
dam
administr
vector
may
thu
effici
strategi
overcom
maternalderiv
immun
vector
deriv
celo
viru
avian
adenoviru
evalu
chicken
celo
vector
express
antigen
infecti
bursal
diseas
viru
induc
protect
upon
inject
chicken
ovo
oral
deliv
vaccin
anim
diseas
sought
eas
administr
repres
mean
immunis
wildlif
whose
major
role
reservoir
pathogen
agent
underscor
indepth
analysi
origin
emerg
human
diseas
importantli
oral
vaccin
hold
promis
elicit
immun
respons
system
also
mucos
surfac
repres
major
site
pathogen
entri
respons
poorli
elicit
inject
vaccin
certain
observ
suggest
effect
oral
vaccin
might
well
deriv
ad
particular
oral
deliv
adbas
vaccin
acut
respiratori
diseas
ard
adenovir
origin
administ
militari
personnel
usa
period
year
begin
vaccin
compos
replicationcompet
form
enter
coat
tablet
welltoler
afford
signific
level
protect
ard
vaccin
product
discontinu
similar
adderiv
vaccin
ard
process
relicens
regard
oral
deliveri
human
ad
express
heterolog
antigen
mani
experiment
vaccin
evalu
divers
speci
upon
oral
administr
vector
express
glycoprotein
rabi
viru
fox
vaccine
develop
na
rabi
viru
dog
immun
respons
detect
oral
administr
even
endoscop
deposit
small
intestin
regard
oral
deliveri
ad
nonprim
origin
antigenspecif
immun
respons
elicit
transgen
product
rodent
model
well
veterinari
speci
includ
pig
dog
upon
oral
deliveri
pig
protect
oral
challeng
although
antibodi
neutralis
csfv
infect
detect
pig
receiv
two
oral
dose
one
protect
diseas
contact
challeng
despit
absenc
serum
na
similar
percentag
pig
vaccin
subcutan
rout
protect
csfv
antigen
found
spleen
surviv
orallyvaccin
subcutaneouslyvaccin
pig
oral
administr
pav
vector
express
transmiss
gastroenter
viru
tgev
spike
protein
induc
tgevspecif
virusneutralis
antibodi
swine
moreov
coronavirusspecif
secretori
iga
detect
small
intestin
lung
immunis
anim
bavderiv
vector
shown
elicit
mucos
immun
induc
protect
natur
host
cattl
even
anim
preexist
antibodi
vector
vector
express
glycoprotein
rabi
viru
administ
cat
parenter
local
rout
intramuscular
neither
intranas
oral
administr
elicit
na
afford
protect
lethal
challeng
contrast
oral
vaccin
dog
bait
contain
elicit
viru
na
afford
longlast
protect
fatal
diseas
upon
challeng
rabi
viru
chicken
protect
challeng
follow
oral
vaccin
fowl
adenoviru
express
spike
subunit
avian
infecti
bronchiti
viru
order
develop
effect
orallydeliv
vaccin
sever
object
must
met
includ
stabil
highli
degrad
gastrointestin
milieu
efficaci
antigen
deliveri
across
mucos
barrier
gutassoci
immuneinduct
tissu
induct
immun
despit
local
immunolog
context
bias
toward
immunolog
toler
given
inher
obstacl
oral
administr
perhap
surpris
present
oral
deliveri
ad
proven
entir
satisfactori
antigenspecif
immun
respons
elicit
rodent
primat
model
well
feral
veterinari
speci
includ
fox
dog
cat
pig
nevertheless
immun
respons
consid
weak
particularli
larg
anim
differ
rout
infect
compar
higher
dose
requir
gener
achiev
detect
system
humor
respons
protect
oral
administr
present
rel
contribut
variou
obstacl
oral
vaccin
unknown
must
appreci
improv
upon
current
ad
vector
oral
deliveri
strategi
suboptim
transduct
secondari
ineffici
breach
like
major
factor
inde
low
amount
genom
ad
dna
detect
stomach
small
intestin
peyer
patch
compar
high
amount
oral
caviti
whether
low
level
express
due
inactiv
ad
vector
gastrointestin
milieu
mucos
barrier
unknown
unlik
howev
gastric
inactiv
repres
obstacl
stomach
bypass
direct
enter
administr
sheep
endoscop
deposit
small
intestin
dog
adapt
immun
respons
weak
undetect
respect
nevertheless
gastroprotect
adbas
vaccin
activ
explor
final
poor
immunolog
context
gastrointestin
milieu
would
seem
factor
oral
adjuv
particular
doubl
strand
rna
analog
gave
rise
improv
adapt
ir
magnitud
also
qualiti
immun
respons
gener
oral
administr
ad
come
scrutini
particular
oral
deliveri
ad
mice
give
rise
system
rather
intestin
cellmedi
immun
upon
oral
deliveri
mice
strong
immun
respons
elicit
transgen
product
lymphocyt
spleen
extrem
limit
immun
respons
peyer
patch
similarli
oral
deliveri
ad
chimpanze
origin
mice
weak
respons
elicit
lymphocyt
spleen
peyer
patch
mesenter
lymph
node
present
unclear
oral
deliveri
ad
elicit
local
humor
local
cellmedi
immun
respons
despit
elicit
system
albeit
weak
cellmedi
immun
respons
nevertheless
view
power
proof
principl
provid
vaccin
like
solut
found
optimis
adenovir
vaccin
oral
administr
baculovirus
member
famili
baculovirida
genera
granuloviru
nucleopolyhedroviru
larg
envelop
virus
doublestrand
circular
dna
genom
kbp
size
far
baculovirus
found
arthropod
restrict
host
rang
made
baculovirus
attract
biolog
agent
insect
pest
control
best
studi
baculoviru
autographa
californica
multicapsid
nucleopolyhedroviru
acmnpv
kbp
acmnpv
genom
dna
infecti
packag
rodshap
nucleocapsid
whose
length
proport
genom
size
enabl
insert
larg
foreign
dna
segment
acmnpv
extens
use
product
recombin
protein
insect
cell
sinc
earli
sinc
time
method
gener
isol
recombin
baculovirus
continu
improv
hofmann
et
al
boyc
bucher
demonstr
acmnpv
recombin
carri
mammalian
cellact
express
cassett
socal
bacmam
virus
suitabl
vector
gene
deliveri
hepat
cell
success
transduct
larg
number
primari
mammalian
cell
establish
cell
line
bacmam
viru
report
exampl
see
kost
condrey
also
effici
gene
transfer
cell
avian
piscin
origin
demonstr
thu
appear
uptak
acmnpv
vertebr
cell
common
event
shown
viral
envelop
glycoprotein
essenti
viru
attach
subsequ
releas
nucleocapsid
endosom
exact
mechan
entri
noninsect
cell
howev
need
clarifi
last
year
increas
number
bacmam
viru
applic
publish
confirm
advantag
bacmam
technolog
gene
deliveri
vertebr
cell
bacmam
virus
easi
gener
broad
cell
type
rang
detect
gene
express
driven
acmnpv
promot
replic
vertebr
cell
littl
microscop
observ
cytopath
effect
transduc
cell
cultur
applic
transient
stabl
express
applic
costeffect
comparison
chemic
transfect
procedur
initi
vivo
transduct
neg
transgen
express
due
inactiv
viru
presenc
nativ
serum
shown
complement
system
mediat
neutral
classic
altern
pathway
overcom
problem
complement
resist
virus
gener
display
human
decay
acceler
factor
viral
envelop
modif
result
enhanc
gene
transfer
effici
neonat
rat
altern
bacmam
virus
pseudotyp
g
protein
vesicular
stomat
viru
vsvg
demonstr
result
virus
resist
inactiv
anim
sera
unmodifi
bacmam
virus
recombin
display
vsvg
protein
envelop
prove
suitabl
vivo
gene
transfer
cerebr
cortex
testi
mice
mous
skelet
muscl
rat
brain
rabbit
muscl
far
report
deal
applic
bacmam
technolog
induct
immun
respons
viral
pathogen
limit
aoki
et
al
inocul
mice
intramuscularli
intranas
acmnpv
recombin
express
pseudorabi
viru
glycoprotein
b
gb
intramuscular
inocul
yield
higher
gbspecif
antibodi
titr
sera
mucos
antibodi
found
intranas
inocul
strauss
et
al
inject
mice
intramuscularli
seri
acmnpv
recombin
display
plasmodium
falciparum
circumsporozoit
cs
protein
viral
envelop
contain
mammalian
cellact
cs
protein
express
cassett
display
express
cs
protein
latter
induc
higher
cs
proteinspecif
antibodi
titr
greater
amount
antigen
specif
produc
cell
virus
display
express
cs
protein
cs
displayexpress
bacmam
viru
also
perform
better
induc
cs
proteinspecif
tcell
respons
vitro
studi
also
reveal
splenocyt
acmnpv
infect
mice
produc
number
nonspecif
produc
cell
lead
assumpt
vector
induc
gener
activ
lymphocyt
interpret
line
previou
report
show
acmnpv
induc
antivir
activ
mammalian
cell
confer
protect
lethal
encephalomyocard
viru
influenza
viru
infect
mice
addit
recent
studi
demonstr
acmnpv
strong
adjuv
also
adapt
immun
respons
mice
effect
humor
tcell
adapt
respons
coinject
antigen
induc
mention
pseudotyp
bacmam
virus
vsvg
improv
vivo
gene
transfer
confer
resist
complementmedi
neutral
improv
induct
antigenspecif
immun
respons
pseudotyp
virus
address
facciaben
et
al
compar
immunogen
properti
convent
vsvg
display
bacmam
virus
express
hepat
c
viru
glycoprotein
contrast
antibodi
respons
compar
differ
virus
less
pseudotyp
viru
need
minim
dose
induct
specif
cellular
immun
respons
nevertheless
virus
induc
cell
antigen
specif
effector
function
pseudotyp
bacmam
viru
also
use
compar
induct
prrsv
neutral
antibodi
mice
inocul
recombin
viru
coexpress
prrsv
protein
dna
immun
purifi
dna
encod
antigen
studi
show
prrsv
neutral
antibodi
rais
dose
depend
manner
astonishingli
twofold
inocul
plaqu
form
unit
bacmam
viru
elicit
significantli
higher
neutral
antibodi
titr
dual
inject
g
purifi
plasmid
dna
field
exampl
applic
bacmam
virus
rapidli
grow
develop
next
gener
bacmam
vector
vaccin
purpos
improv
enhanc
transduct
efficaci
vivo
includ
display
specif
ligand
surfac
bacmam
virion
augment
transgen
express
vertebr
cellact
transcript
posttranscript
regulatori
element
virus
classifi
famili
paramyxovirida
envelop
singlestrand
negativesens
rna
virus
includ
highli
preval
human
pathogen
respiratori
syncyti
viru
rsv
measl
viru
mv
well
virus
major
econom
impact
poultri
livestock
industri
eg
newcastl
diseas
viru
ndv
rinderpest
viru
rpv
pest
de
petit
rumin
pprv
extraordinari
progress
made
past
year
genet
engin
rna
virus
provid
opportun
allow
design
new
vaccin
express
foreign
epitop
potenti
combat
pathogen
major
breakthrough
occur
revers
genet
system
abil
rescu
rna
viru
complet
dna
copi
genom
establish
negativesens
rna
virus
first
viru
rescu
copi
genom
rabi
viru
quickli
follow
rescu
neg
sens
rna
virus
tabl
abil
specif
alter
genom
chosen
site
led
better
understand
viru
protein
function
interact
enabl
develop
live
attenu
viru
vaccin
particular
marker
vaccin
use
associ
companion
diagnost
test
use
identifi
vaccin
oppos
natur
infect
anim
anoth
applic
use
viru
vaccin
vector
deliv
immunogen
pathogen
agent
famili
paramyxovirida
divid
two
subfamili
paramyxovirina
contain
morbilliviru
respiroviru
rubulaviru
two
new
genera
henipaviru
avulaviru
pneumovirina
contain
pneumoviru
metapneumoviru
genera
paramyxovirus
nonseg
negativesens
rna
genom
kb
length
one
characterist
viru
famili
negativestrand
rna
virus
nake
rna
transfect
cell
infecti
contrast
fulllength
genom
rna
positivesens
rna
virus
minimum
protein
requir
rna
transcript
initi
infect
associ
nucleoprotein
n
phosphoprotein
p
polymeras
l
rna
genom
compon
function
activ
ribonucleoprotein
complex
rnp
current
techniqu
recoveri
viru
infecti
clone
revers
genet
involv
cotransfect
permiss
eukaryot
cell
plasmid
express
mrna
viral
rnp
protein
fulllength
genom
rna
express
rna
gener
control
phage
promot
polymeras
suppli
cell
prior
infect
recombin
poxviru
express
protein
live
attenu
strain
virus
extraordinarili
good
induc
humor
immun
respons
cellular
immun
importantli
case
ndv
mv
pprv
rpv
vaccin
individu
complet
protect
homolog
viru
challeng
display
viru
shed
sign
diseas
also
induc
lifelong
protect
either
singl
twodos
administr
moreov
produc
larg
scale
countri
distribut
low
cost
ndv
vaccin
administ
drink
water
spray
flock
make
feasibl
vaccin
larg
popul
poultri
field
low
cost
paramyxoviru
genom
accommod
addit
genet
inform
enabl
express
least
one
foreign
antigen
insert
gene
stabli
maintain
serial
passag
cell
cultur
desir
characterist
paramyxovirida
vaccin
engin
develop
recombin
vector
vaccin
abl
express
high
level
foreign
protein
use
immunis
infect
homolog
viru
infecti
agent
explor
potenti
paramyxovirida
vaccin
vector
number
investig
gener
recombin
virus
major
scientif
human
veterinari
import
feasibl
approach
first
demonstr
introduc
report
gene
genom
human
rsv
prototyp
member
genu
pneumoviru
sendai
viru
subsequ
number
research
group
use
paramyxovirus
express
foreign
protein
includ
footandmouth
diseas
viru
polymeras
pol
part
capsid
protein
rpv
vaccin
strain
green
fluoresc
protein
gfp
g
glycoprotein
vsv
substitut
read
frame
envelop
glycoprotein
haemagglutinin
h
fusion
f
mv
protein
west
nile
viru
flavivirus
mv
vaccin
strain
cdna
develop
maker
vaccin
diva
strategi
import
veterinari
vaccin
exampl
vaccin
live
attenu
vaccin
combat
newcastl
diseas
highli
effect
vaccin
poultri
distinguish
infect
wildtyp
viru
thu
make
difficult
detect
wild
type
virus
may
circul
order
overcom
problem
recombin
viru
gener
express
ndv
f
protein
chimer
haemagglutinin
hn
protein
whose
immunogen
globular
head
replac
avian
paramyxoviru
type
protect
neutral
antibodi
ndv
f
protein
produc
vaccin
produc
hn
protein
allow
serolog
distinct
vaccin
wildtyp
ndv
infect
anoth
studi
delet
bcell
immunodomin
epitop
ctermin
region
n
protein
ndv
gener
effici
negativemark
vaccin
success
result
indic
possibl
find
sequenc
n
protein
highli
immunogen
dispens
viru
growth
delet
sequenc
affect
efficaci
recov
ndv
vaccin
sinc
nspecif
immun
respons
absolut
requir
protect
poultri
lethal
challeng
pandem
spread
highli
pathogen
avian
influenza
viru
hpaiv
special
import
sinc
pose
signific
threat
anim
human
health
number
studi
explor
possibl
creat
safe
recombin
virus
express
protect
protein
strain
would
overcom
safeti
limit
hinder
product
widespread
use
current
influenza
vaccin
field
haemagglutinin
ha
subtyp
hpaiv
express
recombin
vaccin
strain
ndv
viru
use
success
vaccin
larg
number
anim
recent
studi
wildtyp
mutat
ha
open
read
frame
hpaiv
deriv
wild
bird
isol
insert
intergen
region
p
matrix
gene
lasota
ndv
vaccin
strain
singl
dose
recombin
virus
chicken
induc
ndvand
aiv
antibodi
complet
protect
chicken
challeng
lethal
dose
velogen
ndv
homolog
heterolog
hpaiv
approach
similar
ndv
bcell
epitop
delet
n
protein
gene
rinderpest
replac
pprv
exchang
delet
rinderpestspecif
epitop
n
protein
chimer
viru
act
effect
marker
vaccin
rpv
anoth
promis
approach
marker
vaccin
develop
exchang
glycoprotein
member
relat
paramyxovirida
sinc
protein
immunogen
protect
replac
correspond
gene
part
gene
anoth
viru
give
rise
new
viabl
chimer
viru
glycoprotein
exchang
respiroviru
pneumoviru
genera
first
step
way
develop
attenu
bival
live
vaccin
two
import
viral
pathogen
bovin
respiratori
tract
brsv
brsv
gycoprotein
g
f
replac
hn
f
protein
bovin
similarli
envelop
protein
exchang
within
morbilliviru
genu
f
h
protein
gene
rinderpest
viru
replac
pprv
use
rpv
vaccin
backbon
goat
protect
virul
ppr
challeng
result
chimer
ppr
marker
vaccin
widespread
use
vaccin
along
diagnost
test
identifi
serolog
signatur
would
greatli
improv
surveil
capabl
diseas
prepared
emerg
prevent
procedur
among
rhabdovirida
famili
caus
agent
three
differ
import
diseas
rabi
bovin
ephemer
fever
vesicular
stomat
particular
rabi
viru
rv
vesicular
stomat
viru
vs
use
viral
vector
vaccin
vehicl
employ
revers
genet
viral
nonseg
neg
strand
rna
genom
becam
access
genet
manipul
rv
vsv
accept
addit
transcript
unit
maintain
unexpect
genet
stabil
modifi
genom
due
life
cycl
member
rhabdovirida
recombin
revers
integr
viral
genom
host
genom
occur
mani
foreign
gene
insert
express
rhabdovirusbas
vector
vsv
express
foreign
protein
high
level
highli
cytopathogen
infect
cell
rv
noncytopath
infect
cell
express
modest
high
level
foreign
protein
virus
viral
vector
deriv
virus
highli
immunogen
elicit
humor
cellular
innat
immun
effector
pathway
addit
mechan
viral
interfer
effici
viralvector
spread
might
contribut
success
vaccin
use
rhabdovir
vector
applic
kind
vector
eas
due
almost
complet
absenc
seroposit
human
anim
biolog
vector
safeti
concern
exist
address
virus
attenu
strain
gener
molecular
virolog
manipul
major
focu
attenu
viral
glycoprotein
modifi
substitut
glycoprotein
delet
viral
gene
product
contribut
virul
phophosprotein
also
target
modif
anoth
method
achiev
attenu
rv
vsv
rearrang
gene
order
within
genom
approach
appear
shift
balanc
viral
gene
express
viral
replic
toward
express
bunyavirida
famili
largest
known
famili
anim
rna
virus
repres
import
human
anim
arthropod
rodentborn
pathogen
bunyavirida
triseg
neg
sens
rna
virus
revers
genet
system
describ
member
genu
bunyaviru
recent
foreign
gene
express
demonstr
first
time
bunyaviru
mean
rift
valley
fever
viru
driven
revers
genet
system
delet
viral
interferon
antagonist
gene
nss
highli
attenu
viru
provid
room
insert
foreign
sequenc
attenu
viru
still
propag
type
iifndefici
cell
line
remain
highli
immunogen
elicit
effici
neutral
antibodi
respons
abil
bunyaviru
infect
mani
vertebr
cell
make
attract
candid
futur
develop
viral
vector
viral
vector
potenti
antigen
deliveri
strategi
veterinari
speci
found
studi
deal
human
pathogen
good
exampl
express
strategi
reli
use
replicationdefici
alphaviru
modifi
express
foreign
antigen
use
candid
vaccin
anticanc
gene
therapi
strategi
alphavirus
belong
togavirida
famili
contain
kb
ssrna
genom
two
orf
first
one
encod
nonstructur
protein
second
one
encod
structur
protein
control
subgenom
promot
three
prototyp
virus
sindbi
sin
semliki
forest
viru
sfv
venezuelan
equin
enceph
viru
vee
three
type
vector
system
engin
replicationdefici
viral
particl
replicon
particl
replicationcompet
viral
particl
dnarnabas
vector
vaccin
studi
address
mous
model
exampl
relat
anim
diseas
vee
replicon
vector
express
two
major
envelop
protein
equin
arter
viru
eav
use
hors
vaccin
virul
eav
challeng
studi
togeth
other
human
pathogen
demonstr
abil
alphavirus
induc
protect
mucos
respons
hors
intranas
intrauterin
eav
challeng
therefor
interest
aspect
alphaviru
replicon
particl
potenti
abil
induc
mucos
immun
also
shown
sin
sfv
addit
abil
vee
sin
glycoprotein
target
dendrit
cell
report
mice
human
use
selfrepl
alphaviru
dna
vector
contain
rnapol
ii
promot
may
provid
altern
increas
immun
stimul
least
mice
antigen
specif
immun
respons
obtain
lower
dna
dose
compar
convent
plasmid
sinbas
dna
vector
use
prime
immun
respons
aujezski
diseas
pig
decreas
strongli
quantiti
plasmid
need
coronaviru
basedvector
emerg
high
potenti
vaccin
develop
coronavirus
cov
sever
advantag
viral
vector
cov
singlestrand
positivesens
rna
virus
replic
cytoplasm
without
dna
intermediari
make
integr
viru
genom
host
cell
genom
unlik
ii
virus
largest
rna
viru
genom
principl
room
insert
larg
foreign
gene
iii
pleiotrop
secretori
immun
respons
best
induc
stimul
gutassoci
lymphoid
tissu
sinc
cov
gener
infect
mucos
surfac
respiratori
enter
cov
may
use
target
antigen
enter
respiratori
area
induc
strong
secretori
immun
respons
iv
tropism
cov
may
engin
modifi
gene
v
nonpathogen
cov
strain
infect
speci
interest
human
porcin
bovin
canin
felin
avian
avail
therefor
suitabl
develop
safe
viru
vector
vi
infecti
cov
cdna
clone
avail
design
express
system
revers
genet
cov
first
achiev
target
recombin
soon
first
cov
infecti
cdna
clone
construct
transmiss
gastroenter
cov
tgev
achiev
follow
develop
infecti
cdna
clone
human
coronaviru
hcov
sever
acut
respiratori
syndrom
coronaviru
sarscov
mous
hepat
viru
mhv
avian
coronaviru
use
tgev
infecti
cdna
maintain
bac
green
fluoresc
protein
gfp
gene
success
express
replac
nonessenti
gene
sequenc
encod
gfp
engin
genom
stabl
passag
cultur
cell
led
product
high
protein
level
cell
use
vector
bicistron
express
two
surfac
protein
porcin
respiratori
reproduct
syndrom
viru
prrsv
viru
protein
shown
ten
passag
tissu
cultur
viru
infect
cell
express
protein
respect
l
enjuan
person
commun
vector
also
use
bicistron
express
rotaviru
viral
protein
self
aggreg
lead
format
rotaviru
like
particl
vlp
cytoplasm
infect
cell
j
ceriani
j
buesa
l
enjuan
javier
ortego
unpublish
result
therefor
express
level
use
vector
similar
describ
vector
deriv
posit
strand
rna
virus
sindbi
viru
use
tgevderiv
vector
express
gfp
induct
lactogen
immun
demonstr
recombin
tgev
also
assembl
vitro
junction
six
cdna
fragment
encod
fulllength
genom
use
system
gfp
gene
replac
lead
product
tgev
grew
titr
pfuml
express
gfp
high
proport
cell
final
covderiv
viru
vector
engin
infecti
bronchiti
viru
ibv
gfp
protein
express
replac
nonessenti
gene
recombin
viru
grew
titr
lower
wild
type
viru
gfp
express
lost
earli
passag
propagationdefici
covderiv
vector
also
gener
base
replicon
deriv
tgev
advantag
system
increas
room
insert
foreign
gene
compar
fulllength
infecti
cdna
structur
gene
delet
ii
possibl
engin
multigen
express
vector
due
transcript
strategi
cov
iii
increas
level
safeti
replicon
noninfecti
tgevderiv
replicon
gener
infecti
cdna
gfp
protein
success
express
replicon
high
express
level
transfect
cell
replicon
deriv
express
gfp
also
gener
cell
level
increas
cotransfect
n
protein
mrna
multigen
vector
base
replicon
also
construct
express
gfp
chloranphenicol
acetyltransferas
cat
firefli
luciferas
luc
heterolog
gene
express
level
gfpposit
cell
cat
level
cell
luc
activ
around
rel
light
cell
human
covbas
vector
rna
pack
propagationdefici
pseudovirion
turn
use
transduc
immatur
matur
human
dendrit
cell
safe
replicationcompet
propagationdefici
viru
vector
base
tgev
genom
defici
essenti
gene
e
obtain
use
e
packag
cell
line
also
develop
two
type
cell
line
construct
express
transient
stabli
e
protein
tgev
viru
titr
directli
relat
e
protein
express
level
higher
transient
express
cell
line
absenc
e
protein
immatur
tgev
particl
size
slightli
larger
matur
virus
form
particl
releas
supernat
infect
cultur
wherea
infecti
virus
assembl
packag
cell
line
provid
e
protein
tran
abil
gener
tgeve
mutant
replicationcompet
propagationdefici
complement
packag
cell
line
support
potenti
use
coronaviru
vaccin
vector
among
retrovirida
famili
foami
virus
subfamili
spumavirina
lentivirus
subfamili
lentivirina
constitut
potenti
deliveri
ssrna
viral
vector
lentivir
vector
consid
promis
vaccin
vector
sinc
good
induc
protect
ctl
respons
effici
transduc
dendrit
cell
therefor
ensur
induct
th
cell
respons
correct
develop
antibodi
respons
among
common
advantag
lentivir
vector
genet
stabil
express
vaccin
antigen
period
time
favour
trigger
immun
respons
recent
lentivir
vector
tripsewnv
express
solubl
form
wnv
glycoprotein
e
strain
induc
strong
longlast
neutral
antibodi
respons
singl
ip
dose
mice
antibodi
respons
correl
full
protec
tabl
advantag
disadvantag
differ
antigen
deliveri
system
tion
observ
mice
lethal
wnv
challeng
addit
potenti
replicationcompet
felin
foami
viru
ffv
base
vaccin
vector
vaccin
purpos
investig
ffv
vector
express
neutral
epitop
felin
caliciviru
fcv
capsid
protein
induc
humor
respons
vector
protein
heterolog
capsid
antigen
challeng
cat
homolog
fcv
viru
shed
diseas
specif
clinic
sign
significantli
reduc
vector
deriv
bovin
lentiviru
jembrana
diseas
viru
jdv
develop
mean
gener
bicistron
transfer
vector
jdvbase
vector
could
pseudotyp
vsvg
protein
exhibit
broad
tropism
use
vaccin
develop
new
emerg
vector
may
also
provid
opportun
gener
novel
deliveri
system
novel
viralvector
base
prototyp
live
attenu
vaccin
yellow
fever
use
vector
system
develop
vaccin
flavivirus
includ
west
nile
viru
approach
interchang
gene
encod
coat
protein
yf
correspond
flavivirus
gener
chimer
virus
also
use
success
gener
chimer
virus
novel
vaccin
pestivirus
yf
base
vector
possibl
use
csfv
attenu
vector
express
heterolog
gene
swine
explor
larg
number
differ
strategi
vaccin
antigen
deliveri
avail
mani
offer
consider
advantag
classic
vaccin
tabl
howev
yet
predict
appropri
deliveri
technolog
make
effect
vaccin
still
know
certain
antigen
appear
work
better
other
use
deliveri
system
reductionist
vaccin
approach
seek
look
singl
antigen
antigen
determin
deliv
use
heterolog
express
system
may
clear
advantag
includ
safeti
eas
product
may
compromis
immunogen
therefor
vaccin
effici
nonreductionist
vaccin
approach
aim
find
way
ration
attenu
virul
specif
pathogen
base
exampl
found
literatur
approach
render
effect
vaccin
howev
rais
safeti
concern
extrem
plethora
differ
strategi
provid
good
compromis
safeti
effici
yet
lack
data
regard
field
perform
whether
vaccin
appli
livestock
speci
pet
industri
avoid
spread
pathogen
nonendem
locat
depend
biosafeti
consider
experiment
data
spite
advanc
field
strategi
reach
final
valid
field
use
anim
health
polici
requir
improv
vaccin
usual
delay
preclud
implement
field
contrast
experiment
vaccin
shed
light
understand
immun
mechan
elicit
host
abl
confer
protect
diseas
point
view
deliveri
system
essenti
tool
vaccin
develop
